HARBIN, China, March 19 /PRNewswire-Asia/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced the receipt of Conformite Europeenne (CE) certification for its Myocardial Infarction and Urine Microalbumin Diagnostic Kits. The CE marking certifies that the two products have met the European Union (EU) health and safety standards and are approved for sale in the 27 EU countries and four members of the European Free Trade Association (EFTA).
The Company also received ISO 9001 and ISO 13485 certifications for its Myocardial Infarction, Urine Microalbumin and Early Pregnancy Diagnostic Kits. ISO certifications set stringent, globally recognized management system standard that enhances its product marketing. The two ISO certifications are valid through October 2014.
Investors can visit the Company's website http://www.cski.com.cn , under the section of News, to view all these certifications.
"We are honored to receive the CE marking and the ISO certifications, which reinforce the high quality of our products and manufacturing standards and pave way for exporting the diagnostic kits in the EU and other markets," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "According to agreements with our distributors in Indonesia, Turkey, Singapore and Vietnam, we will enter into definitive contracts with the distributors following receipt of the CE marking. The CE marking and ISO certifications also strengthen the Company's ability to advance our negotiations with potential distributors from many other countries. We look forward to launching our diagnostic kits in promising international markets beginning in 2010."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include expectations of the effect of receiving CE, ISO 9001 and ISO 13485 certifications. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Stanley Hao, CFO
Tel: +86-451-8703-2617
Email: stanleyhao@cski.com.cn
Investor Relations Contact:
CCG Investor Relations
Ms. Lei Huang, Account Manager
Tel: +1-646-833-3417
Email: lei.huang@ccgir.com
Web: http://www.ccgirasia.com
Ms. Mabel Zhang, Vice President
Tel: +1-310-954-1353
Email: mabel.zhang@ccgir.com
